Home Analyst Ratings Janney Capital raises Chatham Lodging ’s rating to Buy

Janney Capital raises Chatham Lodging [CLDT]’s rating to Buy

Janney Capital took its Chatham Lodging [CLDT] rating to the equivalent of Buy from Neutral, in a research note dated 2021-01-06. Other analysts also revised their coverage, with B. Riley FBR’s analysts upgrading the shares from “a Neutral” rating to “a Buy” rating in a research note to investors issued in late March. Meanwhile, BMO Capital Markets had launched its coverage on CLDT with “Market perform”, in a research note produced for clients October 17, 2019. In addition, there was no change from B. Riley FBR Inc. on February 27, 2018. The rater maintained CLDT to “a Neutral” but assigned new target price of $20.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is Chatham Lodging Trust [NYSE:CLDT] a Good Buy Right Now?

It should be noted that CLDT technical indicators for short, intermediate as well as long term progress have placed an overall average of 72% as Buy. The average signal changed from 88% Buy in the last week and compares with 100% Buy in the past month. Data from Chatham Lodging Trust’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.32 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.35 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.4 million shares.

CLDT Price Performance

On Wall Street, Chatham Lodging Trust [NYSE:CLDT] finished Tuesday’s session up 1.72% at $10.64. The stock went up to $10.85 at the same session while its lowest single day price was $10.43. In the last five days, it saw a fall of about -5.59%, Chatham Lodging Trust shares dropped by almost -1.48% since the beginning of the year. However, the share price has dropped to as low as -41.57% below its one year high. On 01/04/21, the company shares recorded $10.97, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $10.26. The company’s shares have declined by -40.16% in the past year. The 50-day SMA achieved is $10.28 while the 200-day SMA is $7.58. Volume dropped to 0.23 million from 0.34 million in the previous session.

CLDT Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 10.43 level, and in case of violation of this particular level, it will cause more drop to 10.22 level. On the upper level, 11.06 is still the key resistance. The stock may increase to the subsequent resistance at 10.85. The Relative Strength Index (RSI) pinned on the 14-day chart is 44.26, implying a neutral technical stance while the MACD stands at -0.55, meaning price will decrease in the next trading period. Percent R indicator moved to 77.78%, implying bearish price movement. Stochastic %K at 13.71% suggest selling the stock.

What is the short interest in Chatham Lodging Trust?

Short interest in the Chatham Lodging Trust stock has plunged, decreasing by -0.32 million shares to total 1.78 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 1.46 million, data from Yahoo Finance shows. The increase of 17.98% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 5.56% of the overall float for the stock.

Chatham Lodging Trust’s Biggest Shareholders: Who Owns Chatham Lodging Trust [CLDT]?

Filings by BlackRock Fund Advisors showed that the firm now holds a total of 6,627,532 shares or roughly 14.11% of the outstanding CLDT shares. This means their shares have reduced by -377,075 from the 6,627,532 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, The Vanguard Group, Inc. updated stake is worth $56,971,873. Details in the latest 13F filings reveal that Fuller & Thaler Asset Management, disposed off their -5.55% stake valued at $33,412,719 while SSgA Funds Management, Inc. cut theirs at $25,437,361. During the last quarter, Fuller & Thaler Asset Management, liquidated -178,356 of its shares in Chatham Lodging Trust while SSgA Funds Management, Inc. sold -154,400 shares. The Renaissance Technologies LLC’s holdings currently number 1,742,555 shares at $18540785.2. According to the firm’s last 13F report, Northern Trust Investments, Inc. shares in the company at filing stood at 1,062,279 shares, roughly $11,695,692.

CLDT Earnings Forecast For The Current Quarter

Chatham Lodging Trust [CLDT] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $36.98M and an earnings per share of -$0.45 for Dec 2020. Looking further ahead, the company is expected to report revenue of $43.24M at an EPS of -$0.44 for Mar 2021. The estimates represent downside of 40.10% and 59.50% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

CLDT Earnings Estimates For The Current Year

For the financial year, Chatham Lodging Trust [NYSE:CLDT] is expected to bring in revenue of $149.61M. The returns are nearly $-178.72 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -2.1, lower than that of FY19 by -$2.49. Estimates put this year’s earnings growth at -638.50%, 59.50% for the next, and at an annual 12.00% over the next 5-year period. As for sales, forecasts are for a decrease of -54.40% in the current fiscal year and a further 40.10% over the following year.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Prompted INVO Biosciences’ After-Hours Rally?

A spike in INVO Bioscience, Inc's (NASDAQ: INVO) stock price after-hours drove its price up 83.28% on Monday. In regular sessions, through the end...

The Opgen (OPGN) Stock Is High Today, Reason?

OpGen, Inc. (Nasdaq: OPGN), a company that makes use of the power of molecular diagnostics and bioinformatics to treat infectious diseases, is showing strength...

Why Nano Dimension (NNDM) Leapt 7% In Aftermarket Trading On Friday?

After-hours trading on Friday saw Nano Dimension Corp (Nasdaq: NNDM) hit $7.97 a share rising 4.73%. The stock saw a decline of -2.31% to...

What Caused The Anchiano Therapeutics (ANCN) To Continue Rally After-Hours?

The clinical-stage biotech company Anchiano Therapeutics Ltd. (Nasdaq: ANCN) saw its stock rising 40.12% in after-hours trades on Friday. The price of the company’s...

Are The Financial Results Weighing On Senseonics (SENS) Stock In Premarket Today?

Shares of medical technology Senseonics Holdings, Inc. (NYSE American: SENS) has been declining -9.67% in pre-market session today falling to a price level of...

Tron (TRX) Working Hard on DeFi Development; Where is TRX Heading?

Tron 2021 Global DeFi Hackathon developer contest is one of its $120 million TRON DeFi Entrepreneurial Alliance Support Program.  TRON (TRX) is making sure that it...

Mark Cuban backs Dogecoin (DOGE) and says Dallas Mavericks are the largest merchant of Meme Coin worldwide

After Elon Musk, Cuban comes out in favor of the meme coin. Dogecoin (DOGE) is one of the most anticipated cryptocurrencies of the future. Back...

The Opgen (OPGN) Stock Is High Today, Reason?

OpGen, Inc. (Nasdaq: OPGN), a company that makes use of the power of molecular diagnostics and bioinformatics to treat infectious diseases, is showing strength...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.